Array Biopharma Inc (NASDAQ:ARRY) Shorted Shares Increased By 8.25%

September 16, 2018 - By Vernon Prom

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Investors sentiment decreased to 1.12 in 2018 Q2. Its down 0.62, from 1.74 in 2018Q1. It turned negative, as 33 investors sold Array BioPharma Inc. shares while 57 reduced holdings. 29 funds opened positions while 72 raised stakes. 190.66 million shares or 0.50% more from 189.71 million shares in 2018Q1 were reported.
Wellington Mngmt Llp holds 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY) for 512,917 shares. 992,392 are owned by Goldman Sachs Grp. Segall Bryant Hamill Ltd Liability reported 36,779 shares. 46,712 were reported by Jpmorgan Chase. Ameriprise Fincl reported 162,995 shares. Piedmont Investment Advsr Ltd accumulated 3,540 shares or 0% of the stock. Farallon Capital Mngmt Ltd Com holds 0.48% or 4.65 million shares in its portfolio. North Star Investment Mgmt reported 0.19% in Array BioPharma Inc. (NASDAQ:ARRY). Neuberger Berman Gru Ltd Liability invested in 740,025 shares or 0.01% of the stock. 280,671 are owned by Fiera Cap. Schwab Charles Invest Management stated it has 1.16M shares or 0.01% of all its holdings. Baker Bros Advsrs Ltd Partnership holds 0.71% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY) for 5.66 million shares. Qcm Cayman Ltd, Texas-based fund reported 12,332 shares. Castleark Mngmt Limited Liability Company invested 0.17% in Array BioPharma Inc. (NASDAQ:ARRY). Dupont Management holds 0.03% or 81,070 shares.

Since March 21, 2018, it had 0 insider purchases, and 14 insider sales for $9.02 million activity. Robbins Andrew R also sold $318,681 worth of Array BioPharma Inc. (NASDAQ:ARRY) shares. Another trade for 77,576 shares valued at $1.46 million was sold by Sandor Victor. Squarer Ron had sold 184,253 shares worth $3.31M on Wednesday, June 27. $278,400 worth of Array BioPharma Inc. (NASDAQ:ARRY) shares were sold by Haddock Jason. $872,500 worth of stock was sold by LEFKOFF KYLE on Friday, July 6.

The stock of Array Biopharma Inc (NASDAQ:ARRY) registered an increase of 8.25% in short interest. ARRY’s total short interest was 14.63 million shares in September as published by FINRA. Its up 8.25% from 13.51 million shares, reported previously. With 2.24M shares average volume, it will take short sellers 7 days to cover their ARRY’s short positions.

The stock increased 0.07% or $0.01 during the last trading session, reaching $13.85. About 1.49 million shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 38.92% since September 16, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $2.94 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

Among 4 analysts covering Array Biopharma (NASDAQ:ARRY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Array Biopharma had 5 analyst reports since May 10, 2018 according to SRatingsIntel. Cowen & Co maintained Array BioPharma Inc. (NASDAQ:ARRY) on Tuesday, June 5 with “Buy” rating. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Outperform” rating by Wells Fargo on Thursday, June 28. The firm has “Overweight” rating by Cantor Fitzgerald given on Monday, June 25. The firm earned “Buy” rating on Thursday, May 10 by Cowen & Co. As per Monday, June 25, the company rating was maintained by Piper Jaffray.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by: Streetinsider.com, which released: “Array Biopharma (ARRY) Reports Publication of BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) Phase 3 Overall …” on September 13, 2018. Seekingalpha.com‘s article titled: “Your Cancer Highlight: Loxo Breaks Through Again, Now With Its Own Drug” and published on September 07, 2018 is yet another important article.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.